Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 2, 2004, Pages 369-377

  Mueller, Markus ^a,b   De La Peña, Amparo ^a   Derendorf, Hartmut ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ALGORITHM; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM; BIOLOGICAL MODEL; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DATA ANALYSIS; DIFFUSION; DILUTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG DOSE; DRUG EFFECT; HUMAN; IN VITRO STUDY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SHORT SURVEY; SIMULATION; TIME KILL CURVE;

ALGORITHMS; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL;

EID: 0942268852     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.2.369-377.2004     Document Type: Short Survey

References (121)

1. Aeschlimann, J. R., and M. J. Rybak, 1998. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faccium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob. Agents Chemother. 42:2188-2192.
2. Amyes, S. 1999. Ten years of ciprofloxacin: the past, present and future. Antimicrobial susceptibility. J. Antimicrob. Chemother. 43(Suppl. A): 1-2.
3. Andes, D. R., and W. A. Craig. 1998. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin. Infect. Dis. 27:47-50.
4. Andes, D. R., and W. A. Craig. 1999. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect. Dis. Clin. North Am. 13:595-618.
5. Bellido, F., J. C. Pechere, and E. W. Hancock. 1991. Novel method for measurement of outer membrane permeability to new b-lactams in intact Enterobacter cloacae cells. Antimicrob. Agents Chemother. 35:68-72.
6. Bergan, T., I. B. Carlsen, and J. E. Fuglesang. 1980. An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions. Infection. 8:S96-102.
7. Bergan, T., and I. B. Carlsen. 1980. Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions. Infection. 8:S103-107.
8. Bergan, T., and I. B. Carlsen. 1985. Effect of antibiotics eliminated by first order kinetics. J. Antimicrob. Chemother. 15:147-152.
9. Birkness, K. A., M. Deslauriers, J. H. Bartlett, et al. 1999. An in vitro tissue culture bilayer model to examine early events in Mycobacterium tuberculosis infection. Infect. Immun. 67:653-658.
10. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
11. Blaser, J. and C. Konig. 1995. Once-daily dosing of aminoglycosides. Eur. J. Clin. Microbiol. Infect. Dis. 14:1029-1038.
12. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Two compartment kinetic model with multiple artificial capillary units. J. Antimicrobial Chemotherapy. 15:131-137.
13. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob. Agents Chemother. 27:343-349.
14. Blaser, J., B. Stone, M. C. Groner, and S. H. Zinner. 1985. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 28:64-68.
15. Blaser, J., P. Vergeres, A. F. Widmer, and W. Zimmerli. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139.
16. Chambers, H. F., and S. Kennedy. 1990. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob. Agents Chemother. 34:510-514.
17. Chambers, H. F., M. Sachdeva, and S. Kennedy. 1990. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 162:705-710.
18. Corvaisier, S., P. H. Maire, X. Barbaut, N. Bleyzac, and R. W. Jelliffe. 1998. Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob. Agents Chemother. 42:1731-1737.
19. Craig, W. A. 1998. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J. 77:7-11.
20. Craig, W. A. 1996. Antimicrobial resistance issues of the future. Diagn Microbiol Infect. Dis. 25:213-217.
21. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
22. Craig, W. A. 1995. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA Eur. J. Clin. Microbiol. Infect. Dis. 14:636-642.
23. a. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect. Dis. 22:89-96.
24. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis medium. Pediatr. Infect. Dis. J. 15:255-259.
25. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27:29-40.
26. Dalla Costa, T., and H. Derendorf. 1996. AUIC-a general target for the optimization of dosing regimens of antibiotics? Ann. Pharmacother. 30:1024-1028.
27. Dalla Costa, T., A. Nolting, K. Rand, and H. Derendorf. 1997. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int. J. Clin. Pharmacol. Ther. 35:426-433.
28. Darouiche, R. O., A. Dhir, A. J. Miller, et al. 1994. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. J. Infect. Dis. 170:720-723.
29. Derendorf, H. 1989. Pharmacokinetic evaluation of beta-lactam antibiotics. J. Antimicrob. Chemother. 24:407-413.
30. Derendorf, H., and B. Meibohm. 1999. Modeling of pharmacokinetic/pharmacodynamic (pharmacokinetic-pharmacodynamic relationships: concepts and perspectives. Pharm. Res. 16:176-185.
31. DiPiro, J. T., C. E. Edmiston, Jr., and J. M. Bohnen. 1996. Pharmacodynamics of antimicrobial therapy in surgery. Am. J. Surg. 171:615-622.
32. Drake, T. A., W. M. Scheld, and M. A. Sande. 1985. Effects of sub-bactericidal concentrations of antibiotics in experimental models of endocarditis. J. Antimicrob. Chemother. 15:293-296.
33. Drusano, G. L. 1998. Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Clin. Infect. Dis. 27(Suppl. 1):S111-1116.
34. Drusano, G. L. 1990. Human pharmacodynamics of beta-lactams, amino-glycosides and their combination. Scand. J. Infect. Dis. Suppl. 74:235-248.
35. Eagle, H., and A. D. Musselman. 1948. The rate of bacterial action of penicillin in vitro as a function of its concentration, and its paradoxically reduces activity at high concentrations against certain organisms. J. Exp. Med. 88:99-131.
36. Eden, T. 1985. Long-standing otitis medium with effusion-a convenient model for the study of antibiotic penetration to respiratory tract secretions. Scand. J. Infect. Dis. Suppl. 44:46-51.
37. Firsov, A. A., V. M. Chernykh, and S. M. Navashin. 1990. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob. Agents Chemother. 34:1312-1317.
38. Firsov, A. A., S. N. Vostrov, A. A. Shevehenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
39. Firsov, A. A., A. A. Shevehenko, S. N. Vostrov, and S. H. Zinner. 1998. Inter- and intraquinolone predictos of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 42:659-665.
40. Firsov, A. A., S. N. Vostrov, A. A. Shevehenko, Y. A. Portnoy, and S. H. Zinner. 1998. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob. Agents Chemother. 42:2841-2847.
41. Firsov, A. A., R. G. Vasilov, S. N. Vostrov, O. V. Kononenko, I. Y. Luhenko, and S. H. Zinner. 1999. Prediction of the antimicrobial effects of trovafloxacin and cirofloxacin on staphylococci using an in-vitro dynamic model. J. Antimicrob. Chemother. 43:483-490.
42. Firsov, A. A., S. N. Vostrov, O. V. Kononenko, S. H. Zinner, and Y. A. Portnoy. 1999. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 43:498-502.
43. Firsov, A. A., M. Ruble, D. Gilbert, et al. 1997. Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model. Antimicrob. Agents Chemother. 41:7-12.
44. Flaherty, J. F., S. L. Barriere, J. Mordenti, J. G. Gambertoglio. 1987. Effect of Dose on Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin. Antimicrob. Agents Chemother. 31:895-898.
45. Flaherty, J. F., L. C. Rodondi, B. J. Guglielmo, J. C. Fleishaker, R. J. Townsend, and J. G. Gambertoglio. 1988. Comparative Pharmacokinetics and Serum Inhibitory Activity of Clindamycin in Different Dosing Regimens. Antimicrob. Agents Chemother. 32:1825-1829.
46. Francioli, P., and M. P. Glauser. 1985. Successful prophylaxis of experimental streptococcal endocarditis with single doses of sublethal concentrations of penicillin. J. Antimicrob. Chemother. 15:297-302.
47. Frimodt-Moller, N., M. W. Bentzon, and V. F. Thomsen. 1986. Experimental infection with Streptococcus pneumoniac in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J. Infect. Dis. 154:511-517.
48. Garrett, E. R. 1978. Kinetics of Antimicrobial Action. Scand. J. Infect. Dis. 14:54-85.
49. Garrett, E. R., G. H. Miller, and M. R. Brown. 1966. Kinetics and mechanisms of action of antibiotic on microorganisms. V. Chloramphenicol and tetracycline affected Escherichia coli generation rates. J. Pharm. Sci. 55:593-600.
50. Garrett, E. R., and H. Nolte. 1972. Kinetics and Mechanisms of Drug Action on Microorganisms. XIV. The Action of Flourouracil, other Uracils and Derived Nucleosides on the Microbial Kinetics of Escherichia coli. Chemotherapy. 17:81-107.
51. Garrett, E. R., and C. M. Won. 1973. Kinetics and Mechanisms of Drug Action on Microorganisms. XVII: Bactericidal Effects of Penicillin, Kanamicyn, and Rifampin with and without Organism Pretreatment with Bacteriostatic Chloramphenicol, Tetracycline, and Novobiocin. J. Pharm. Sci. 62:1666-1673.
52. Gengo, F. M., T. W. Mannion, C. H. Nightingale, and J. J. Schentag. 1984. Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. J. Antimicrob. Chemother. 14:619-631.
53. Gerber, A. U., C. Feller, and H. P. Brugger. 1984. Time course of the pharmacological response to beta-lactam antibiotics in vitro and in vivo. Eur. J. Clin. Microbiol. 3:592-597.
54. Grasso, S., G. Meinardi, de Carneri, I., and V. Tamassia. 1978. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob. Agents Chemother. 13:570-576.
55. Greenwood, D., and F. O'Grady. 1978. An in vitro model of the urinary bladder. J. Antimicrob. Chemother. 4:113-120.
56. Greenwood, D. 1985. An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis. J. Antimicrob. Chemother. 15:103-109.
57. Hoffman, A., and D. Stepensky. 1999. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst. 16:571-639.
58. Hollenstein, U., M. Brunner, B. X. Mayer, et al. 2000. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin. Pharmacol. Ther. 67:229-236.
59. Hulten, K., R. Rigo, I. Gustafsson, and L. Engstrand. 1993. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Antimicrob. Agents Chemother. 40:2727-2731.
60. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet. 28:143-160.
61. Hyatt, J. M., D. E. Nix, and J. J. Schentag. 1994. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob. Agents Chemother. 38:2730-2737.
62. Hyatt, J. M., and J. J. Schentag. 2000. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 21:S9-11.
63. Hyatt, J. M., and J. J Schentag. 2000. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. Infect. Control Hosp. Epidemiol. 21:S18-21.
64. Jusko, W. J. 1971. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J. Pharm. Sci. 60:892-895.
65. Keil, S., and B. Wiedemann. 1995. Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models. Antimicrob. Agents Chemother. 39:1054-1058.
66. Knudsen, J. D., K. Fuursted, S. Raher, F. Espersen, and Frimodt- N. Moller. 2000. Pharmacodynamics of glycopeptides in the mouse peritonitis model of streptococcus pneumoniae or staphylococcus aureus infection. Antimicrob. Agents Chemother. 44:1247-1254.
67. König, P., J. P. Guggenbichler, E. Semenitz, and W. Foisner. 1986. Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. 1. Description of the model. Chemotherapy. 32:37-43.
68. König, P., J. P. Guggenbichler, E. Semenitz, and W. Foisner. 1986. Kill Kinetics of bacteria under Fluctuating Concentrations of Various Antibiotics. II. Description of Experiments. Chemotherapy. 32:44-58.
69. Kutlin, A., P. M. Roblin, and M. R. Hammerschlag. 1999. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob. Agents Chemother. 43:2268-2272.
70. Ledergerber, B., J. Blaser, and R. Luthy. 1985. Computer-controlled in-vitro simulation of multiple dosing regimens. J. Antimicrob. Chemother. 15:169-173.
71. Leggett, J. E., B. Fantin, S. Ebert, et al. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292.
72. Li, R. C., M. Zhu, and J. J. Schentag. 1999. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin. Pharmacokinet. 37:1-16.
73. List, T. P. 1996. Continuous infusion of beta-lactam antibiotics: a potential strategy to improve parenteral antimicrobial therapy. A Consensus Document. University of Oklahoma, Oklahoma City, Okla.
74. Löwdin, E., I. Odenholt, S. Bengtsson, and O. Cars. 1996. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrob. Agents Chemother. 40:2478-2482.
75. Löwdin, E., I. Odenholt, and O. Cars. 1998. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 42:2739-2744.
76. Mattie, H. 1981. Kinetics of antimicrobial action. Rev. Infect. Dis. 3:19-27.
77. Mattie, H. 1978. A Mathematical Description of Short-Term Effects of Beta-lactam Antibiotics on Bacterial Growth In Vitro. Curr. Microbiol. 1:105-109.
78. Mattie, H., and van der Voet, G. B. 1979. Influence of aminopenicillins on bacterial growth kinetics in vitro in comparison with the antibacterial effect in vivo. Infection. 7:S434-437.
79. McCormack, J. P., and J. J. Schentag. 1987. Potential Impact of Quantitative Susceptibility Tests on the Design of Aminoglycoside Dosing Regimens. Drug Intelligence Clin. Pharm. 21:187-191.
80. McGrath, B. J., S. L. Kang, G. W. Kaatz, and M. J. Rybak. 1994. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob. Agents Chemother. 38:2034-2040.
81. Meibohm, B., and H. Derendorf. 1997. Basic concepts of pharmacokinetic/pharmacodynamic (pharmacokinetic-pharmacodynamic) modelling. Int. J. Clin. Pharmacol. Ther. 35:401-413.
82. Mentec, H., J. M. Vallois, A. Bure, et al. 1992. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Antimicrob. Agents Chemother. 36:1883-1889.
83. Mielck, J. B., and E. R. Garrett. 1969. Kinetics and mechanisms of drug action on microorganisms. IX. Inhibitory action of lincomycin on Escherichia coli by microbial kinetics. Chemotherapy. 14:337-355.
84. Moise, A., and J. Schentag. 1998. Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy. Curr. opinion in Infectious Diseases. II: 673-680.
85. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
86. Mordenti, J. J., R. Quintiliani, and C. H. Nightingale. 1985. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J. Antimicrob. Chemother. 15:313-321.
87. Murakawa, T., H. Sakamoto, T. Hirose, and M. Nishida. 1980. New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics. Antimicrob. Agents Chemother. 18:377-381.
88. National Committee for Clinical Laboratory Standards. 1997. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that grow aerobically. 4th. ed. Approved Standard. NCCLS Publication No. M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
89. Nightingale, C. 1980. Pharmacokinetics of the oral cephalosporins in adults. J. Int. Med. Res. 8:2-8.
90. Nolting, A. 1994. Pharmacokinetic-pharmacodynamic modeling of the antibacterial effects of piperacillin. University of Florida, Gainesville, Fla.
91. Nolting, A., Dalia Costa, T., K. H. Rand, and H. Derendorf. 1996. Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm. Res. 13:91-96.
92. Odenholt, T. I. 1989. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model. Scand. J. Infect. Dis. Suppl. 58:1-55.
93. Onyeji, C. O., D. P. Nicolau, C. H. Nightingale, and R. Quintiliani. 1994. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections. Antimicrob. Agents Chemother. 38:1112-1117.
94. Palmer, S. M., S. L. Kang, D. M. Cappelletty, and M. J. Rybak. 1995. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob. Agents Chemother. 39:1764-1771.
95. Palmer, S. M., and M. J. Rybak. 1997. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. J. Antimicrob. Chemother. 39:515-518.
96. Peterson, L. R., J. A. Moody, C. E. Fasching, and D. N. Gerding. 1989. Influence of protein binding on therapeutic efficacy of cefoperazone. Antimicrob. Agents Chemother. 33:566-568.
97. Reeves, D. S. 1985. Advantages and disadvantages of an in-vitro model with two compartments connected by a dialyser: results of experiments with ciprofloxacin. J. Antimicrob. Chemother. 15:159-167.
98. Reigner, B. G., P. E. Williams, I. H. Patel, et al. 1997. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin. Pharmacokinet. 33:142-152.
99. Renard, L., P. Sanders, M. Laurentie, and J. M. Delmas. 1996. Pharmacokinetic-pharmacodynamic model for spiramycin in staphylococcal mastitis. J. Vet. Pharmacol. Ther. 19:95-103.
100. Sanchez-Navarro, A., and Sanchez Recio, M. M. 1999. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation. Clin. Pharmacokinet. 37:289-304.
101. Sanchez-Recio, M. M., C. I. Colino, and Sanchez-Navarro, A. 2000. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. J. Antimicrob. Chemother. 45:321-328.
102. Sanfilippo, A., and E. Morvillo. 1968. An Experimental Model for the Study of the Antibacterial Activity of the Sulfonamides. Chemotherapy. 13:54-60.
103. Sanfilippo, A., and G. Schioppacassi. 1973. New approach to the evaluation of antibacterial activity of aminosidine. Chemotherapy. 18:297-303.
104. Sano, M., Y. Kumamoto, M. Nishimura, T. Tsukamoto, T. Hirose, and S. Ohya. 1994. Inhibition of biofilm formation by clarithromycin (CAM) in an experimental model of complicated bladder infection-in vitro study using automated simulation of urinary antimicrobial concentration. Kansenshogaku Zasshi. 68:1306-1317.
105. Schentag, J. J. 1999. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients. Am. J. Health Syst Pharm. 56:S21-4.
106. Schentag, J. J. 1999. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J. Chemother. 11:426-439.
107. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Ann. Pharmacother. Dicp. 25:1050-1057.
108. Schentag, J. J., Strenkoski-Nix, L. C., D. E. Nix, and A. Forrest. 1998. Pharmacodynamic interactions of antibiotics alone and in combination. Clin. Infect. Dis. 27:40-46.
109. Stratton, C. W., M. P. Weinstein, and L. B. Reller. 1982. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. J. Infect. Dis. 154:160-168.
110. Thauvin, C., G. M. Eliopoulos, S. Willey, C. Wennersten, and R. C. Moellering, Jr. 1974. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob. Agents Chemother. 31:139-143.
111. Thomas, J. K., A. Forrest, S. M. Bhavnani, et al. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527.
112. Tran, J. Q., C. H. Ballow, A. Forrest, et al. 2000. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. J. Antimicrob. Chemother. 45(Suppl.)B:9-17.
113. Turnidge, J. D. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22.
114. Vance-Bryan, K., T. A. Larson, M. W. Garrison, et al. 1992. An in vitro pharmacodynamic model to simulate antibiotic behavior of acute otitis medium with effusion. Pharmaceutical Research. 9:920-924.
115. van der Voet, G. B., H. Mattie, and van Furth, R. 1985. Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutropenic mice. J. Antimicrob. Chemother. 16:605-613.
116. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
117. Vondracek, T. G. 1995. Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann. Pharmacother. 29:415-424.
118. White, C. A., R. D. Toothaker, A. L. Smith, and J. T. Slattery. 1987. Correction for bacterial loss in in vitro dilution models. Antimicrob. Agents Chemother. 31:1859-1860.
119. Zhi, J., C. H. Nightingale, and R. Quintiliani. 1988. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J. Pharmacokinet. Biopharm. 16:355-375.
120. Zinner, S. H., and J. Blaser. 1986. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. J. Antimicrob. Chemother. 17:1-5.
121. Zinner, S. H., J. Blaser, B. B. Stone, and M. C. Groner. 1985. Use of an in-vitro kinetic model to study antibiotic combinations. J. Antimicrob. Chemother. 15:221-226.